Barclays PLC grew its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 149.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 230,177 shares of the company's stock after purchasing an additional 137,936 shares during the quarter. Barclays PLC owned approximately 0.16% of Adaptive Biotechnologies worth $1,180,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company grew its stake in Adaptive Biotechnologies by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company's stock worth $177,000 after buying an additional 2,710 shares during the last quarter. Vontobel Holding Ltd. grew its position in shares of Adaptive Biotechnologies by 30.8% during the third quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company's stock worth $87,000 after acquiring an additional 4,000 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptive Biotechnologies during the third quarter worth about $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in shares of Adaptive Biotechnologies by 29.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company's stock worth $131,000 after acquiring an additional 5,826 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in Adaptive Biotechnologies in the 3rd quarter valued at about $34,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.
Adaptive Biotechnologies Trading Down 6.0 %
ADPT traded down $0.39 on Tuesday, reaching $6.07. The company had a trading volume of 971,149 shares, compared to its average volume of 1,541,183. The company has a market capitalization of $895.80 million, a P/E ratio of -4.53 and a beta of 1.47. The company has a fifty day moving average of $6.04 and a 200-day moving average of $5.04. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $7.46.
Analyst Ratings Changes
ADPT has been the subject of several recent analyst reports. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler increased their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an "overweight" rating in a report on Monday, November 11th.
Check Out Our Latest Report on Adaptive Biotechnologies
Adaptive Biotechnologies Profile
(
Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
See Also
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
